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Low Coenzyme Q10 Levels
nd the Outcome of
tatin Treatment in Heart Failure
McMurray et al. (1) investigated in a pre-specified substudy of
CORONA (Controlled Rosuvastatin Multinational Study in Heart
Failure) the effect of statin therapy on plasma coenzyme Q10 (CoQ10)
oncentration and the possible relationship between the level of
oQ10 and cardiovascular events. Depletion of tissue CoQ10, a
owerful natural antioxidant and an essential component of the
espiratory chain, might explain at least in part the neutral outcome of
he rosuvastatin study. Rosuvastatin treatment at 10 mg/day reduced
lasma CoQ10 significantly by 39%, down to a median level that was
ower than the baseline level of CoQ10 in patients classified in tertile
(0.48 g/ml). With a focus on the number of clinical outcomes in
atients in tertile 1, more patients in the rosuvastatin group compared
ith those receiving placebo experienced primary end points (72 vs.
9, respectively); also, greater all-cause mortality (78 vs. 67) and
oronary end points (54 vs. 45) were recorded in the rosuvastatin-
reated patients. These differences were calculated to be not statisti-
ally significant but according to the undersigned clinically relevant.
he investigators expressed some caution in their discussion of a
ossible adverse effect of statin treatment in patients with low CoQ10
levels: “We cannot completely exclude an adverse effect,” and “we had
limited statistical power to exclude this possibility” (1). In a previous
study by Molyneux et al. (2), the investigators found low CoQ10
concentration to be an independent predictor of mortality in patients
with heart failure, and the association was even stronger than with
N-terminal pro–B-type natriuretic peptide.
The optimal design of a controlled statin trial in heart failure
should have a CoQ10 plus statin arm to evaluate outcomes in 2
spects: 1) to avoid further depletion of the plasma and tissue levels
f CoQ10 in heart failure (3); and 2) to derive advantage from a
possible therapeutic effect of CoQ10 in addition to conventional
herapy (4).
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Reply
Plasma coenzyme Q10 (CoQ10) concentration was not an indepen-
dent predictor of any major clinical outcome in the elderly patients
with quite advanced heart failure in CORONA (Controlled Rosuv-
astatin Multinational Study in Heart Failure) (1). Looking at the
outcomes that should be most sensitive to any harmful effect of
lowering CoQ10, there was no convincing effect of rosuvastatin on
ither the risk for heart failure hospitalization or the composite of
eath or heart failure hospitalization. Prior studies of CoQ10 supple-
mentation in heart failure have not shown any convincing benefit.
Although it would be of interest to study a statin with and without
CoQ10 supplementation, such a trial is very unlikely to be conducted.
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Assessment of Psychosocial Risk
Factors Is Missing in the
2010 ACCF/AHA Guideline
for Assessment of Cardiovascular
Risk in Asymptomatic Adults
Despite the amount of evidence supporting significant and indepen-
dent associations between psychosocial factors and the pathogenesis of
cardiovascular disease (1–5), the 2010 American College of Cardiol-
ogy Foundation/American Heart Association Guideline for Assess-
ment of Cardiovascular Risk in Asymptomatic Adults (6) does not
consider any of them and does not provide any justification for that
decision. This is surprising because many studies have shown that
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April 5, 2011:1568–71psychosocial factors such as clinical depression, hostility/anger, and
acute/chronic mental stress have cardiovascular risk gradients compa-
rable to or steeper than the risk gradients of more traditional risk
factors such as elevated cholesterol (2,4). Furthermore, it is well
known that emotional outbursts in asymptomatic but vulnerable
individuals can trigger acute coronary syndromes (7). We wonder
what the reason is for such an omission in cardiovascular risk
stratification and primary prevention, and we call for recognition of
psychosocial factors because whatever physiologic or behavioral mecha-
nisms link them to the pathogenesis and expression of heart disease,
recognition and treatment of at least depression, hostility/anger, and
chronic psychologic stress may lead to cardiovascular risk reduction
throughmodification of the adverse physiologic and behavioral correlates.
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Guidelines for Assessment
of Cardiovascular Disease
in Life Insurance
The Task Force that prepared the 2010 American College of
Cardiology Foundation/American Heart Association Guidelines
for Assessment of Cardiovascular Risk in Asymptomatic Adults
(1) included representatives of societies of echocardiography,
nuclear cardiology, imaging, angiography, computed tomography,
and cardiovascular magnetic resonance imaging. It is surprisingthat there were no representatives of the group with the greatest
experience and professional interest in the subject—physicians and
cardiologists in the life insurance industry. This industry was the
first to accept the importance of brachial cuff blood pressure as a
measure of risk in 1917 and the first to use radial artery tonometry
and pulse waveform analysis to reject applicants for life insurance
even earlier (2).
It is surprising too that the views of the task force with respect
to aortic stiffness and pulse wave analysis conflict with those of the
European Societies of Hypertension and of Cardiology (3), which
see the value of such measurements for the prediction of risk. The
European societies considered mechanism and history in prepara-
tion of their guidelines, whereas the U.S. task force did not—they
concentrated on evidence available up to 2009/2010 from identi-
fication of “key words.” However, none of the key words that relate
to arterial aging were considered, not even such basic words as
“aging,” “aortic stiffness,” “pulse wave analyses,” “pulse wave
velocity,” “wave reflection,” or “tonometry.” If the key words are
not sought, the “evidence” will not be available.
There are multiple prospective studies (4–6) that justify a Level of
vidence: A rather than a Level of Evidence: C, including meta-
nalyses presented by Roman (7) and by Vlachopoulos et al. (5,6).
The purpose of the life insurance industry is to provide the
ommunity with life coverage on the basis of the best risk
nformation available. Tests that can be done to stratify risk cannot
e invasive or involve radiation, must identify risk over and above
onventional risk factors, and must be inexpensive. Pulse wave
elocity and pulse waveform analysis appear to provide such
nformation. We would be grateful if this issue could be reconsid-
red because it applies to the global life insurance industry, which
ooks to the American College of Cardiology Foundation and the
merican Heart Association for leadership and guidance.
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